Fenebrutinib
- Generic Name
- Fenebrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C37H44N8O4
- CAS Number
- 1434048-34-6
- Unique Ingredient Identifier
- E9L2885WUL
- Background
Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 109
- Registration Number
- NCT05119569
- Locations
- 🇷🇸
Clinical Center Nis, NIS, Serbia
🇺🇸Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 746
- Registration Number
- NCT04586010
- Locations
- 🇺🇸
Johns Hopkins University School Of Medicine; Outpatient Center, Baltimore, Maryland, United States
🇺🇸OhioHealth, Columbus, Ohio, United States
🇺🇸The Boster Center for MS, Columbus, Ohio, United States
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 751
- Registration Number
- NCT04586023
- Locations
- 🇦🇹
Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, Austria
🇧🇷L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 985
- Registration Number
- NCT04544449
- Locations
- 🇦🇷
Focus CECIC, Buenos Aires, Argentina
🇺🇸Alabama Neurology Associates, Homewood, Alabama, United States
🇺🇸Sutter East Bay Medical Foundation, Berkeley, California, United States
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT03596632
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.